- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height…
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501…
Parties consider collaborative agreement for the collection and conversion of anesthetic gasesTORONTO, June 19, 2023 (GLOBE NEWSWIRE) -- Blue-Zone Technologies…
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously…
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean…
Figure 1 UPCR % Change With Atacicept 150 mg at Week 36 Figure 2 eGFR % Change With Atacicept 150…
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses…
Restructuring agreement with K2 HealthVentures (K2HV) to fully discharge and satisfy outstanding debt owed to K2HV for the prepayment of…
EAGLE, Idaho, June 16, 2023 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant…
The Company Vended its Debt and Equity Interest in Propagation Services Canada Inc. for an aggregate of $250,000 and Nick…